Trastuzumab emtansine extends life in HER2 breast cancer

Share this content:

Trastuzumab emtansine (T-DM1) significantly improved overall survival of persons with HER2-positive metastatic breast cancer compared with the combination treatment of lapatinib and capecitabine, according to updated results from the drug company testing T-DM1.

A previous interim analysis demonstrated a trend toward improved overall survival in patients receiving T-DM1 compared with those on the lapatinib-plus-Xeloda regimen, but the data were not considered statistically significant at that time. Now, the new confirmatory analysis of overall survival has crossed a prespecified boundary showing that T-DM1 significantly extended survival compared with the other treatment.

Pharmaceutical company Roche (Basel, Switzerland) announced in a press release that new data from the international, phase III EMILIA study shows participants have now met both primary efficacy endpoints of significant improvements in overall survival and progression-free survival. The trial involves 991 persons with HER2-positive locally advanced or metastatic breast cancer who had previously undergone treatment with Herceptin (trastuzumab) and taxane chemotherapy.

Half the group (495 patients) was assigned to receive T-DM1, an antibody-drug conjugate (ADC) under study. Comprised of the antibody trastuzumab and the chemotherapy DM1, T-DM1 is designed to target and inhibit HER2 signaling and deliver DM1 directly inside HER2-positive cancer cells. People in the lapatinib-and-capecitabine arm of the EMILIA study now will be offered the option to receive T-DM1.

Although the Roche statement provided no statistics on overall survival, EMILIA data released in June 2012 showed that among 495 persons given T-DM1, risk of disease progression was 35% lower than that seen among the 496 patients receiving lapatinib plus capecitabine (median progression-free survival 9.6 months vs 6.4 months). In addition, fewer adverse effects of grade 3 or higher were seen in the T-DM1 group.

Genentech, a member of the Roche Group, licenses technology for T-DM1 under an agreement with ImmunoGen, Inc., and has submitted a Biologics License Application for the agent to the FDA. Genentech also manufactures capecitabine under the brand name Xeloda.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs